Review



apc-cy7-conjugated b220 antibody  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Thermo Fisher apc-cy7-conjugated b220 antibody
    Apc Cy7 Conjugated B220 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc-cy7-conjugated b220 antibody/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    apc-cy7-conjugated b220 antibody - by Bioz Stars, 2026-03
    90/100 stars

    Images



    Similar Products

    90
    Thermo Fisher apc-cy7-conjugated b220 antibody
    Apc Cy7 Conjugated B220 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc-cy7-conjugated b220 antibody/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    apc-cy7-conjugated b220 antibody - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Becton Dickinson apc-cy7 b220 (cd45r
    EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + <t>B220</t> + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Apc Cy7 B220 (Cd45r, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc-cy7 b220 (cd45r/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    apc-cy7 b220 (cd45r - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Becton Dickinson apc-cy7 b220 (cd45r) (552094)
    EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + <t>B220</t> + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Apc Cy7 B220 (Cd45r) (552094), supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc-cy7 b220 (cd45r) (552094)/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    apc-cy7 b220 (cd45r) (552094) - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    91
    Cytek Biosciences b220 apc cy7
    EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + <t>B220</t> + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    B220 Apc Cy7, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/b220 apc cy7/product/Cytek Biosciences
    Average 91 stars, based on 1 article reviews
    b220 apc cy7 - by Bioz Stars, 2026-03
    91/100 stars
      Buy from Supplier

    90
    Becton Dickinson b220‐apc‐cy7
    EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + <t>B220</t> + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    B220‐Apc‐Cy7, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/b220‐apc‐cy7/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    b220‐apc‐cy7 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Becton Dickinson b220 ra3-6b2, apc-cy7-conjugated
    EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + <t>B220</t> + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    B220 Ra3 6b2, Apc Cy7 Conjugated, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/b220 ra3-6b2, apc-cy7-conjugated/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    b220 ra3-6b2, apc-cy7-conjugated - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Becton Dickinson apc-cy7 b220
    EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + <t>B220</t> + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Apc Cy7 B220, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc-cy7 b220/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    apc-cy7 b220 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Becton Dickinson apc-cy7 anti-mouse b220 (ra3-6b2) antibody
    EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + <t>B220</t> + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Apc Cy7 Anti Mouse B220 (Ra3 6b2) Antibody, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc-cy7 anti-mouse b220 (ra3-6b2) antibody/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    apc-cy7 anti-mouse b220 (ra3-6b2) antibody - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher b220 apc cy7
    EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + <t>B220</t> + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    B220 Apc Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/b220 apc cy7/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    b220 apc cy7 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    91
    Cytek Biosciences anti b220 apc cy7
    EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + <t>B220</t> + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Anti B220 Apc Cy7, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti b220 apc cy7/product/Cytek Biosciences
    Average 91 stars, based on 1 article reviews
    anti b220 apc cy7 - by Bioz Stars, 2026-03
    91/100 stars
      Buy from Supplier

    Image Search Results


    EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + B220 + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Journal: iScience

    Article Title: Epidermal growth factor augments the self-renewal capacity of aged hematopoietic stem cells

    doi: 10.1016/j.isci.2024.110306

    Figure Lengend Snippet: EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + B220 + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Article Snippet: APC-Cy7 B220 (CD45R) , BD Biosciences , 552094.

    Techniques: In Vitro, Transplantation Assay, Irradiation, Cell Culture

    Journal: iScience

    Article Title: Epidermal growth factor augments the self-renewal capacity of aged hematopoietic stem cells

    doi: 10.1016/j.isci.2024.110306

    Figure Lengend Snippet:

    Article Snippet: APC-Cy7 B220 (CD45R) , BD Biosciences , 552094.

    Techniques: Purification, Recombinant, Enzyme-linked Immunosorbent Assay, Reverse Transcription, Sequencing, Software

    EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + B220 + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Journal: iScience

    Article Title: Epidermal growth factor augments the self-renewal capacity of aged hematopoietic stem cells

    doi: 10.1016/j.isci.2024.110306

    Figure Lengend Snippet: EGF treatment in vitro improves the competitive repopulating capacity of aged HSCs (A) Total cell counts, %KSL cells and % SLAM KSL cells at day +7 of culture of aged BM 34 − KSL cells with Media alone (TSF) or media + EGF (n = 9–10/group, t test). (B) Schematic representation of the competitive transplantation assays performed. Recipient mice irradiated with 875 cGy TBI. (C) Donor CD45.2+ cell engraftment over time in the PB of primary recipient CD45.1+ mice transplanted competitively with the progeny of 500 aged BM 34-KSL cells cultured with media alone or media + EGF x 7 days (n = 9-10/group). (D) Representative flow cytometric analysis of donor CD45.2 + cell engraftment in the PB of CD45.1 + recipient mice at 16 weeks following transplantation as described in (C). (E) Mean percentages of donor CD45.2 + , CD45.2 + Mac-1/Gr-1 + cells, CD45.2 + B220 + cells, and CD45.2 + CD3 + cells in the PB of CD45.1 + recipient mice at 16 weeks post competitive transplantation of the progeny of 500 aged BM 34 − KSL cells treated with media alone or media + EGF ( n = 9–10/group, ANOVA). (F) Representative flow cytometric analysis of donor CD45.2 + cell engraftment within the BM KSL population and within BM CD150 + CD48 − KSL HSCs at week 16 in recipient mice transplanted with the progeny of aged BM 34 − KSL cells treated with media alone or media + EGF. (G) Mean %CD45.2 + KSL cells and %CD45.2 + CD150 + CD48 − KSL (SLAM KSL) cells in recipient mice transplanted with the progeny of culture with media alone or media + EGF ( n = 9/group, t test). (H) Mean percentages of donor CD45.2 + cells in the PB of secondary mice that were transplanted with 1 × 10 6 BM cells collected at 16 weeks from primary recipient mice that were competitively transplanted with the progeny of aged BM 34 − KSL cells cultured × 7 days with media alone or media + EGF ( n = 9/group, t test). Data are represented as means +/− SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Article Snippet: Lineage analysis was performed using PE Mac-1 (CD11b) (Cat # 557397), PE Gr-1 (Ly-6G and Ly-6C) (553128), APC Ter-119 (557909), V450 CD3 (561389), APC-Cy7 B220 (CD45R) (552094) antibodies purchased from BD Biosciences, San Jose, CA.

    Techniques: In Vitro, Transplantation Assay, Irradiation, Cell Culture

    Journal: iScience

    Article Title: Epidermal growth factor augments the self-renewal capacity of aged hematopoietic stem cells

    doi: 10.1016/j.isci.2024.110306

    Figure Lengend Snippet:

    Article Snippet: Lineage analysis was performed using PE Mac-1 (CD11b) (Cat # 557397), PE Gr-1 (Ly-6G and Ly-6C) (553128), APC Ter-119 (557909), V450 CD3 (561389), APC-Cy7 B220 (CD45R) (552094) antibodies purchased from BD Biosciences, San Jose, CA.

    Techniques: Purification, Recombinant, Enzyme-linked Immunosorbent Assay, Reverse Transcription, Sequencing, Software